1. Home
  2. VRAX vs SNGX Comparison

VRAX vs SNGX Comparison

Compare VRAX & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRAX
  • SNGX
  • Stock Information
  • Founded
  • VRAX 2013
  • SNGX 1987
  • Country
  • VRAX United Kingdom
  • SNGX United States
  • Employees
  • VRAX N/A
  • SNGX N/A
  • Industry
  • VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • SNGX Biotechnology: Pharmaceutical Preparations
  • Sector
  • VRAX Health Care
  • SNGX Health Care
  • Exchange
  • VRAX Nasdaq
  • SNGX Nasdaq
  • Market Cap
  • VRAX 7.3M
  • SNGX 7.4M
  • IPO Year
  • VRAX 2022
  • SNGX 1987
  • Fundamental
  • Price
  • VRAX $1.88
  • SNGX $2.44
  • Analyst Decision
  • VRAX
  • SNGX
  • Analyst Count
  • VRAX 0
  • SNGX 0
  • Target Price
  • VRAX N/A
  • SNGX N/A
  • AVG Volume (30 Days)
  • VRAX 282.7K
  • SNGX 40.8K
  • Earning Date
  • VRAX 02-05-2025
  • SNGX 03-14-2025
  • Dividend Yield
  • VRAX N/A
  • SNGX N/A
  • EPS Growth
  • VRAX N/A
  • SNGX N/A
  • EPS
  • VRAX N/A
  • SNGX N/A
  • Revenue
  • VRAX $84,872.00
  • SNGX $364,183.00
  • Revenue This Year
  • VRAX $5,169.18
  • SNGX N/A
  • Revenue Next Year
  • VRAX $66.97
  • SNGX $76.64
  • P/E Ratio
  • VRAX N/A
  • SNGX N/A
  • Revenue Growth
  • VRAX 7.03
  • SNGX N/A
  • 52 Week Low
  • VRAX $0.60
  • SNGX $1.83
  • 52 Week High
  • VRAX $9.00
  • SNGX $14.88
  • Technical
  • Relative Strength Index (RSI)
  • VRAX 48.30
  • SNGX 46.48
  • Support Level
  • VRAX $1.58
  • SNGX $2.25
  • Resistance Level
  • VRAX $2.10
  • SNGX $2.60
  • Average True Range (ATR)
  • VRAX 0.24
  • SNGX 0.15
  • MACD
  • VRAX 0.02
  • SNGX 0.04
  • Stochastic Oscillator
  • VRAX 44.59
  • SNGX 63.64

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Share on Social Networks: